Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 9/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10028651 | 1.00 | FKBP1A (0.47) | FKBP1APDK1PDK2PDK3PDK4 | |
| SCHEMBL994565 | 0.87 | FKBP1A (0.47) | FKBP1APDK1PDK2PDK3PDK4 | |
| SCHEMBL11264038 | 0.81 | FKBP1A (0.53) | FKBP1AFABP7FABP5HPGDALDH1A1 | |
| SCHEMBL25368400 | 0.81 | HPGD (0.47) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL7361872 | 0.78 | FKBP1A (0.48) | FKBP1AALDH1A1 | |
| SCHEMBL17893034 | 0.78 | FKBP1A (0.51) | FKBP1APDK1PDK2PDK3PDK4 | |
| SCHEMBL7361869 | 0.78 | FKBP1A (0.48) | FKBP1AALDH1A1 | |
| SCHEMBL8332542 | 0.78 | FKBP1A (0.51) | FKBP1APDK1PDK2PDK3PDK4 | |
| SCHEMBL17896181 | 0.78 | FKBP1A (0.51) | FKBP1APDK1PDK2PDK3PDK4 | |
| SCHEMBL997332 | 0.78 | FKBP1A (0.42) | FKBP1APDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415766-A1 | METHOD FOR MANUFACTURING BENZODIAZEPINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120010401-A1 | METHOD FOR MANUFACTURING 1,5-BENZODIAZEPINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010401-A1 | METHOD FOR MANUFACTURING 1,5-BENZODIAZEPINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010401-A1 | METHOD FOR MANUFACTURING 1,5-BENZODIAZEPINE DERIVATIVE | GABRA5, CYP3A5, GABRA1 | FKBP1A 1341/4885PDK1 1100/4885PDK2 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.